Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2024 |
Summary of Loss Before Income Taxes |
The Company is subject to taxation in the United States, China , Hong Kong, Australia, and Singapore. Loss before income taxes was as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. operations (domestic) |
|
$ |
7,941 |
|
|
$ |
11,280 |
|
Non-U.S. operations (foreign) |
|
|
28,614 |
|
|
|
9,588 |
|
|
|
|
|
|
|
|
|
|
Loss before provision for income taxes |
|
$ |
36,555 |
|
|
$ |
20,868 |
|
|
|
|
|
|
|
|
|
|
|
Summary of Components of Income Tax Expense |
The significant components of the provision for income taxes are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current expense: |
|
|
|
|
|
|
|
|
Federal |
|
$ |
— |
|
|
$ |
221 |
|
State |
|
|
13 |
|
|
|
19 |
|
Foreign |
|
|
— |
|
|
|
40 |
|
Total current expense: |
|
|
13 |
|
|
|
280 |
|
Deferred expense: |
|
|
|
|
|
|
|
|
Federal |
|
|
— |
|
|
|
— |
|
State |
|
|
— |
|
|
|
— |
|
Foreign |
|
|
— |
|
|
|
— |
|
Total deferred expense: |
|
|
— |
|
|
|
— |
|
Total income tax provision: |
|
$ |
13 |
|
|
$ |
280 |
|
|
|
|
|
|
|
|
|
|
|
Summary of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate |
A reconciliation of the provision for income taxes to the amount computed by applying the statutory federal income tax rate to the net loss is summarized as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Domestic statutory rate |
|
|
21 |
% |
|
|
21 |
% |
Foreign rate differential |
|
|
(9 |
)% |
|
|
4 |
% |
China R&D deduction |
|
|
0 |
% |
|
|
12 |
% |
Nondeductible expenses |
|
|
(1 |
)% |
|
|
0 |
% |
Non-deductible intellectual property rights |
|
|
0 |
% |
|
|
6 |
% |
Tax credits |
|
|
1 |
% |
|
|
2 |
% |
Change in valuation allowance |
|
|
(12 |
)% |
|
|
(46 |
)% |
|
|
|
|
|
|
|
|
|
Total |
|
|
0 |
% |
|
|
(1 |
)% |
|
|
|
|
|
|
|
|
|
|
Summary of Total Deferred Tax Assets |
The significant components of the Company’s deferred tax assets and liabilities for the years ended December 31, 2024 and 2023 are shown below (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred tax assets |
|
|
|
|
|
|
|
|
Net operating losses |
|
$ |
26,334 |
|
|
$ |
23,957 |
|
Intellectual property sale |
|
|
3,405 |
|
|
|
3,405 |
|
Capitalized R&D |
|
|
4,185 |
|
|
|
2,915 |
|
Other |
|
|
994 |
|
|
|
438 |
|
|
|
|
|
|
|
|
|
|
Total deferred tax assets |
|
|
34,918 |
|
|
|
30,715 |
|
Less: valuation allowance |
|
|
(34,779 |
) |
|
|
(30,590 |
) |
Total net deferred tax assets |
|
|
139 |
|
|
|
125 |
|
Deferred tax liabilities |
|
|
|
|
|
|
|
|
|
|
|
(139 |
) |
|
|
(58 |
) |
|
|
|
|
|
|
|
|
|
Other |
|
|
— |
|
|
|
(67 |
) |
Total deferred tax liabilities |
|
|
(139 |
) |
|
|
(125 |
) |
|
|
|
|
|
|
|
|
|
Total net deferred taxes |
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
summary of Company's Net Operating Losses and Tax Credit Carryforwards |
The following table summarizes the Company’s net operating losses and tax credit carryforwards by jurisdiction (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net operating losses: |
|
|
|
|
|
|
|
|
|
|
|
|
U.S. federal |
|
$ |
1,688 |
|
|
$ |
— |
|
|
|
Indefinite |
|
U.S. state |
|
|
9,084 |
|
|
|
1,772 |
|
|
|
2041 |
|
Australia |
|
|
959 |
|
|
|
— |
|
|
|
Indefinite |
|
Hong Kong |
|
|
920 |
|
|
|
902 |
|
|
|
Indefinite |
|
Other China |
|
|
99,555 |
|
|
|
95,291 |
|
|
|
2025 |
|
Tax credits: |
|
|
|
|
|
|
|
|
|
|
|
|
U.S. federal |
|
$ |
671 |
|
|
$ |
255 |
|
|
|
2043 |
|
U.S. state |
|
|
316 |
|
|
|
247 |
|
|
|
Indefinite |
|
|
Summary of Changes in Balance of Gross Unrecognized Tax Benefits |
The following table summarizes the changes to the Company’s gross unrecognized tax benefits (in thousands):
|
|
|
|
|
Unrecognized tax benefit |
|
|
|
Balance at December 31, 2022 |
|
$ |
123 |
|
Additions based on tax positions related to the current year |
|
|
115 |
|
Additions based on tax positions of prior years |
|
|
— |
|
Reductions for tax positions of prior years |
|
|
— |
|
Settlements |
|
|
— |
|
|
|
|
|
|
Balance at December 31, 2023 |
|
|
238 |
|
Additions based on tax positions related to the current year |
|
|
75 |
|
Additions based on tax positions of prior years |
|
|
— |
|
Reductions for tax positions of prior years |
|
|
— |
|
Settlements |
|
|
— |
|
|
|
|
|
|
Balance at December 31, 2024 |
|
$ |
313 |
|
|
|
|
|
|
|
IKENA ONCOLOGY INC |
|
Summary of Components of Income Tax Expense |
The components of income tax expense (benefit) were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2024 |
|
|
2023 |
|
Current |
|
|
|
|
|
|
|
|
Federal |
|
$ |
34 |
|
|
$ |
(237 |
) |
State |
|
|
118 |
|
|
|
68 |
|
|
|
|
|
|
|
|
|
|
Total current provision (benefit) |
|
$ |
152 |
|
|
$ |
(169 |
) |
|
|
|
|
|
|
|
|
|
|
Summary of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate |
The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company’s loss before income taxes as follows:
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2024 |
|
|
2023 |
|
Tax effected at statutory rate |
|
|
21.0 |
% |
|
|
21.0 |
% |
State taxes |
|
|
(0.3 |
) |
|
|
6.4 |
|
Stock compensation |
|
|
(1.3 |
) |
|
|
(1.2 |
) |
|
|
|
(0.9 |
) |
|
|
(0.6 |
) |
Federal research and development credits |
|
|
2.9 |
|
|
|
4.2 |
|
Other |
|
|
(0.1 |
) |
|
|
0.4 |
|
Change in valuation allowance |
|
|
(21.6 |
) |
|
|
(30.0 |
) |
|
|
|
|
|
|
|
|
|
Total |
|
|
(0.3 |
)% |
|
|
0.2 |
% |
|
|
|
|
|
|
|
|
|
|
Summary of Total Deferred Tax Assets |
The Company’s total deferred tax assets are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2024 |
|
|
2023 |
|
Deferred tax asset: |
|
|
|
|
|
|
|
|
Federal net operating loss carryforward |
|
$ |
40,218 |
|
|
$ |
29,529 |
|
State net operating loss carryforward |
|
|
13,145 |
|
|
|
8,581 |
|
R&D credit carryforwards |
|
|
16,339 |
|
|
|
14,589 |
|
Capitalized start-up costs |
|
|
176 |
|
|
|
196 |
|
Accruals and reserves |
|
|
492 |
|
|
|
802 |
|
Stock-based compensation |
|
|
2,444 |
|
|
|
2,381 |
|
Lease liability |
|
|
2,078 |
|
|
|
2,934 |
|
Capitalized R&E |
|
|
38,007 |
|
|
|
44,366 |
|
|
|
|
|
|
|
|
|
|
Total deferred tax asset |
|
|
112,899 |
|
|
|
103,378 |
|
Deferred tax liability: |
|
|
|
|
|
|
|
|
Fixed assets |
|
$ |
(140 |
) |
|
$ |
(603 |
) |
|
|
|
(1,004 |
) |
|
|
(1,554 |
) |
|
|
|
|
|
|
|
|
|
Total deferred tax liability |
|
|
(1,144 |
) |
|
|
(2,157 |
) |
|
|
|
|
|
|
|
|
|
Net deferred tax asset and liability before valuation allowance |
|
|
111,755 |
|
|
|
101,221 |
|
Valuation allowance |
|
|
(111,755 |
) |
|
|
(101,221 |
) |
|
|
|
|
|
|
|
|
|
Net deferred tax asset |
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
Summary of Changes in Balance of Gross Unrecognized Tax Benefits |
The aggregate changes in the balance of gross unrecognized tax benefits were as follows (dollars in thousands):
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2024 |
|
|
2023 |
|
Balance at the beginning of the year |
|
$ |
949 |
|
|
$ |
— |
|
Beginning balance adjustment |
|
|
— |
|
|
|
927 |
|
Increases related to tax positions taken from prior years |
|
|
59 |
|
|
|
22 |
|
|
|
|
|
|
|
|
|
|
Ending balance |
|
$ |
1,008 |
|
|
$ |
949 |
|
|
|
|
|
|
|
|
|
|
|